Akero Therapeutics, Inc. AKRO was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a ...
Akero Therapeutics (AKRO) shares have delivered sizable gains for investors over the past year, with the stock up roughly 72%. Lately, its performance has piqued interest because of strong month and ...
So what does it take for a master perfumer to develop distinctive and classic scents? Yahoo Life Shopping delves into his thoughts, from ideation to getting his perfumes on the shelves. We also asked ...
Akero Therapeutics Inc AKRO reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to nonalcoholic steatohepatitis ...
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Akero Therapeutics, Inc. (AKRO) is a stock that can certainly ...
The average one-year price target for Akero Therapeutics (NASDAQ:AKRO) has been revised to 74.46 / share. This is an increase of 16.10% from the prior estimate of 64.13 dated August 31, 2023. The ...
Akero Therapeutic (NASDAQ: AKRO) stock is down 62% on the back of some drug testing results. The market thinks the results show complete failure - thus the crash in AKRO stock. The company itself ...
Akero Therapeutics (AKRO) is scheduled to report earnings on November 11, 2024. The last reported earnings were for reported on August 9, 2024 for Q2.
Hosted on MSN
Does Akero Therapeutics (AKRO) Have the Potential to Rally 59.14% as Wall Street Analysts Expect?
Akero Therapeutics, Inc. (AKRO) closed the last trading session at $48.12, gaining 1.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results